Delving into the Latest Updates on SciClone Pharmaceuticals Jiangsu Limited Company with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

DNA	1

To evaluate the safety and tolerability of PT-112 injection combined with gemcitabine injection in the treatment of patients with advanced solid tumors. To evaluate the anti-tumor effect of PT-112 injection combined with gemcitabine injection at the recommended dose for Phase II in the treatment of patients with advanced biliary tract cancer.

Start Date13 Apr 2020

Sponsor / Collaborator

Saison Pharmaceutical R&D (Shanghai) Co., Ltd.

[+1]

CTR20171255 / RecruitingPhase 1/2

一项PT-112注射液单药治疗晚期实体瘤患者和晚期肝细胞癌患者的开放性I/II期临床研究

[Translation] An open-label phase I/II clinical study of PT-112 injection as a monotherapy in patients with advanced solid tumors and advanced hepatocellular carcinoma

剂量递增阶段主要目的：评估PT-112注射液治疗晚期实体瘤患者的安全性和耐受性。剂量确认阶段主要目的：评估PT-112注射液以推荐最高安全剂量治疗晚期实体瘤患者的安全性和耐受性； II期试验阶段主要目的：评估PT-112注射液以RP2D剂量治疗晚期肝细胞癌的抗肿瘤作用。

[Translation]

Dose escalation phase: Main purpose: to evaluate the safety and tolerability of PT-112 injection in the treatment of patients with advanced solid tumors. Dose confirmation phase: Main purpose: to evaluate the safety and tolerability of PT-112 injection in the treatment of patients with advanced solid tumors at the highest recommended safe dose. Phase II trial phase: Main purpose: to evaluate the anti-tumor effect of PT-112 injection in the treatment of advanced hepatocellular carcinoma at the RP2D dose.

Start Date07 Mar 2018

Sponsor / Collaborator

SciClone Pharmaceuticals International (Cayman) Development Limited

[+2]

100 Clinical Results associated with SciClone Pharmaceuticals Jiangsu Limited Company

Login to view more data

0 Patents (Medical) associated with SciClone Pharmaceuticals Jiangsu Limited Company

Login to view more data

100 Deals associated with SciClone Pharmaceuticals Jiangsu Limited Company

Login to view more data

100 Translational Medicine associated with SciClone Pharmaceuticals Jiangsu Limited Company

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data